XTNT Share Price | Xtant Medical Holdings, Inc. Stock Analysis & Recommendation

Q: How big is Xtant Medical Holdings, Inc.?

Market Cap: As of Jun 18, Xtant Medical Holdings, Inc. has a market capitalization of 83.61 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Xtant Medical Holdings, Inc. reported net sales of 122.29 million and a net profit of -11.99 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 42.96 million and total assets of 93.84 million.

Q: What does Xtant Medical Holdings, Inc. do?

Overview: Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.Financial Snapshot: Net Sales: 33 Million (Quarterly Results - Mar 2025) Net Profit: 0 Million (Quarterly Results - Mar 2025) Market cap: USD 83.61 Million (Micro Cap)Key Metrics: Debt Equity: 0.65 Return on Equity: -27.33% Price to Book: 1.91Contact Details: Address: 664 Cruiser Ln, BELGRADE MT: 59714-9719 Tel: ['1 406 3880480', '1 877 8891972'] Fax: 1 302 6365454 Website: https://xtantmedical.com/

Q: Is Xtant Medical Holdings, Inc. overvalued or undervalued?

As of 15 May 2024, the valuation grade for Xtant Medical Holdings, Inc. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 2.21 and an EV to Sales ratio of 1.03, which suggest that investors are paying a premium despite the company’s losses. Additionally, the ROE stands at -27.33%, highlighting significant inefficiencies in generating returns for shareholders.In comparison to its peers, Xtant Medical's EV to EBITDA ratio of -38.64 is notably worse than Bioventus, Inc., which has a more favorable EV to EBITDA of 9.72, and Axogen, Inc., which shows a significantly negative P/E of -146.35. The stock has outperformed the S&P 500 with a year-to-date return of 48.98% compared to the index's 12.22%, but this short-term performance does not mitigate the overall valuation concerns.

Q: Is Xtant Medical Holdings, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Xtant Medical Holdings, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands show a bullish trend on the weekly but a mildly bearish trend on the monthly. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the monthly MACD.In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 48.98% compared to the S&P 500's 12.22%. However, over longer periods, such as 3 years and 5 years, the stock has underperformed significantly against the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.3 k

Shareholding (Sep 2025)

FII

0.10%

Held by 8 FIIs

DII

45.33%

Held by 18 DIIs

Promoter

52.60%

How big is Xtant Medical Holdings, Inc.?

22-Jun-2025

As of Jun 18, Xtant Medical Holdings, Inc. has a market capitalization of 83.61 million, with net sales of 122.29 million and a net profit of -11.99 million over the latest four quarters. The company reported shareholder's funds of 42.96 million and total assets of 93.84 million as of Dec 24.

View full answer

What does Xtant Medical Holdings, Inc. do?

22-Jun-2025

Xtant Medical Holdings, Inc. develops and markets regenerative medicine products and medical devices in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $33 million and has a market cap of $83.61 million.

View full answer

Who are in the management team of Xtant Medical Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Xtant Medical Holdings, Inc. includes Sean Browne (President and CEO), John Bakewell, Michael Eggenberg, Robert McNamara, Jeffrey Peters, and Matthew Rizzo, all serving as directors. They oversee the company's operations and strategic direction.

View full answer

Is Xtant Medical Holdings, Inc. overvalued or undervalued?

20-Sep-2025

As of May 15, 2024, Xtant Medical Holdings, Inc. is considered a risky investment due to its overvaluation, negative performance metrics, and significant inefficiencies in generating returns, despite a year-to-date stock performance that has outpaced the S&P 500.

View full answer

Is Xtant Medical Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Xtant Medical Holdings, Inc. shows a mildly bullish trend driven by daily moving averages, despite mixed signals from weekly indicators and underperformance over longer periods, while year-to-date it has outperformed the S&P 500 with a return of 48.98%.

View full answer

Compare Xtant Medical Holdings, Inc. with Similar Stocks

Sight Sciences, Inc.Semler Scientific, Inc.Harvard Bioscience, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 88 Million (Micro Cap)

P/E

50.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.37

Return on Equity

3.48%

Price to Book

1.75

Revenue and Profits:

Net Sales:

33 Million

(Quarterly Results - Sep 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-27.62%

6 Months

-11.74%

1 Year

17.31%

2 Years

-45.86%

3 Years

-18.39%

4 Years

-16.4%

5 Years

-77.39%

Xtant Medical Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

18.78%

EBIT Growth (5y)

46.93%

EBIT to Interest (avg)

-2.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.65

Sales to Capital Employed (avg)

1.39

Tax Ratio

0.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

0.38%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.75

EV to EBIT

16.87

EV to EBITDA

9.82

EV to Capital Employed

1.55

EV to Sales

0.80

PEG Ratio

0.46

Dividend Yield

ROCE (Latest)

9.16%

ROE (Latest)

3.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (1.97%)

Foreign Institutions

Held by 8 Foreign Institutions (0.1%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -5.93% vs 7.60% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -62.86% vs 3,400.00% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.30",
          "val2": "35.40",
          "chgp": "-5.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.70",
          "val2": "5.80",
          "chgp": "-36.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "1.00",
          "chgp": "-10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.30",
          "val2": "3.50",
          "chgp": "-62.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "76.40%",
          "val2": "130.60%",
          "chgp": "-5.42%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 28.48% vs 57.41% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2,442.86% vs 108.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "117.30",
          "val2": "91.30",
          "chgp": "28.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-7.00",
          "chgp": "-12.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.20",
          "val2": "2.90",
          "chgp": "44.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.40",
          "val2": "0.70",
          "chgp": "-2,442.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-103.00%",
          "val2": "-111.30%",
          "chgp": "0.83%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

33.30

35.40

-5.93%

Operating Profit (PBDIT) excl Other Income

3.70

5.80

-36.21%

Interest

0.90

1.00

-10.00%

Exceptional Items

0.00

Consolidate Net Profit

1.30

3.50

-62.86%

Operating Profit Margin (Excl OI)

76.40%

130.60%

-5.42%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is -5.93% vs 7.60% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -62.86% vs 3,400.00% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

117.30

91.30

28.48%

Operating Profit (PBDIT) excl Other Income

-7.90

-7.00

-12.86%

Interest

4.20

2.90

44.83%

Exceptional Items

0.00

Consolidate Net Profit

-16.40

0.70

-2,442.86%

Operating Profit Margin (Excl OI)

-103.00%

-111.30%

0.83%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 28.48% vs 57.41% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2,442.86% vs 108.24% in Dec 2023

All Annual Results

Company CV

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc.

Pharmaceuticals & Biotechnology

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.

Company Coordinates

Company Details

664 Cruiser Ln , BELGRADE MT : 59714-9719

Tel: 1 406 38804801 877 8891972

https://xtantmedical.com/

Registrar Details